# US 2026/0098301 A1 · Methods and systems for processing genetic variations and phenotypes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098301 A1
- Document ID: US20260098301A1
- Status: Published application
- Kind: A1
- Application number: 19/183,496
- Filed: 2025-04-18
- Published: 2026-04-09
- Earliest claimed: 2024-10-08
- Assignees: GeneDx, LLC
- Applicants: GeneDx, LLC
- Inventors: Amber Begtrup; Deanna Alexis Carere; Amanda Lindy; Maria Guillen Sacoto
- Web page: https://patentgrep.com/patent/US20260098301A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides a systems and methods for processing genetic variations and phenotypic data. The systems and methods may be used to generate one or more databases comprising genetic variations and associations with phenotypes. The system and methods may be used to determine a pathogenicity of a genetic variation. The systems and methods may comprise human interpretation using pre-determined criteria.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

A method comprising:
(a) assaying a bodily sample from a subject to generate sequencing information;
(b) computer processing the sequencing information using a gene-phenotype knowledge base to identify a prospective genetic variation and a phenotype associated with the prospective genetic variation;
(c) determining a pathogenicity of the prospective genetic variation,
wherein determining the pathogenicity comprises computer processing the prospective genetic variation and the phenotype identified in (b); and
(d) generating a human interpretation of a clinical significance of the pathogenicity determined in (c), wherein the human interpretation comprises applying a set of pre-determined criteria to the determining in (c).

### Claim 16 (depends on 15)

The method of claim 15, wherein the bodily sample is a buccal sample, a blood sample, a saliva sample, a urine sample, a cell sample, or a tissue sample.

### Claim 17 (depends on 15)

The method of claim 15, wherein (a) comprises extracting DNA from the bodily sample.

### Claim 18 (depends on 17)

The method of claim 17, further comprising preparing a sequencing library from the DNA.

### Claim 19 (depends on 17)

The method of claim 17, wherein (a) comprises subjecting the DNA to a sequencing reaction.

### Claim 20 (depends on 19)

The method of claim 19, wherein the sequencing reaction comprises a whole genome sequencing reaction, or an exome sequencing reaction, or both.

### Claim 21 (depends on 19)

The method of claim 19, further comprising subjecting the DNA, or derivatives thereof to one or more pull down probes.

### Claim 22 (depends on 15)

The method of claim 15, wherein the subject is less than 18 years old, 17 years old, 16 years old, 15 years old, 14 years old, 13 years old, 12 years old, 11 years old, 10 years old, 9 years old, 8 years old, 7 years old, 6 years old, 5 years old, 4 years old, 3 years old, 2 years old, or 1 year old.

### Claim 23 (depends on 15)

The method of claim 15, further comprising obtaining data relating to the phenotype of the subject is based at least in part on medical records or clinical notes.

### Claim 24 (depends on 15)

The method of claim 15, wherein the prospective genetic variation comprises one or more of: a substitution, an insertion, a deletion, a single nucleotide variation, a copy number variation, a mobile element insertion (MEI), or a Uniparental disomy (UPD), or any combination thereof.

### Claim 25 (depends on 15)

The method of claim 15, further comprising prior to (c), performing an orthogonal assay to confirm a presence of the prospective genetic variation.

### Claim 26 (depends on 25)

The method of claim 25, wherein the orthogonal assay comprises a chromosomal microarray analysis (CMA), exon-level ‘exon-array’ microarray, qPCR, multiplex ligation-dependent probe amplification (MLPA), or a Sanger sequencing assay.

### Claim 27 (depends on 15)

The method of claim 15, wherein the prospective genetic variation is classified as likely benign, benign, likely pathogenic, pathogenic, or uncertain significance.

### Claim 28 (depends on 27)

The method of claim 27, wherein a genetic variation classified as likely benign indicates at least about a 90% certainty of benignity.

### Claim 29 (depends on 27)

The method of claim 27, wherein a variant classified as benign indicates at least about a 99% certainty of benignity.

### Claim 30 (depends on 27)

The method of claim 27, wherein a variant classified as likely pathogenic indicates at least about a 90% certainty of pathogenicity.

### Claim 31 (depends on 27)

The method of claim 27, wherein a variant classified as pathogenic indicates at least about a 99% certainty of pathogenicity.

### Claim 32 (depends on 15)

The method of claim 15, wherein the processing comprises using a trained machine learning algorithm.

### Claim 33 (depends on 15)

The method of claim 15, wherein the processing outputs one or more scores indicative of strength of association of the prospective genetic variation with the phenotype associated with the prospective genetic variation.

### Claim 34 (depends on 15)

The method of claim 15, wherein the gene-phenotype knowledge base comprises data derived from two or more related individuals, or published literature, or both.

### Claim 35 (depends on 15)

The method of claim 15, wherein the set of pre-determined criteria is based at least at least in part on one or more of: a frequency of the prospective genetic variation in affected and unaffected populations of a disease or disorder, a variant type, a disease mechanism, segregation patterns of one or more loci, analysis of functional studies, analysis of case studies, or analysis of cohort studies, or any combination thereof.

### Claim 36 (depends on 15)

The method of claim 15, wherein the set of pre-determined criteria is based at least upon data from the subject and a data from a mother or father of the subject.

### Claim 37 (depends on 15)

The method of claim 15, wherein the method is performed in less than 7 days.

### Claim 38 (depends on 15)

The method of claim 15, wherein the method is performed in less than 10 days.

### Claim 39 (depends on 15)

The method of claim 15, wherein the method is performed with an accuracy of at least about 90%.

### Claim 40 (depends on 15)

The method of claim 15, wherein the human interpretation further confirms the phenotype associated with the prospective genetic variation.

### Claim 41 (depends on 40)

The method of claim 40, further comprising, based at least on the presence of the prospective genetic variation and the phenotype associated with the prospective genetic variation, determining that the subject has an elevated risk of having a disease, disorder, or condition.

### Claim 42 (depends on 41)

The method of claim 41, wherein determining that the subject has the elevated risk of having the disease, disorder, or condition comprises a sensitivity of at least about 90%.

### Claim 43 (depends on 41)

The method of claim 41, wherein determining that the subject has the elevated risk of having the disease, disorder, or condition comprises a specificity of at least about 90%.

### Claim 44

A method comprising:
(a) obtaining training information comprising a set of genes and a set of phenotypes;
(b) computer processing the training information to identify a prospective genetic variation and a phenotype associated with the prospective genetic variation;
(c) generating a human interpretation of a clinical significance of an association between the prospective genetic variation and the phenotype,
wherein the human interpretation comprises applying a set of pre-determined criteria to the identifying in (b); and
(d) incorporating the association into a gene-phenotype knowledge base, based at least in part on the human interpretation in (c).
